Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 1008 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... February 14, 2023 Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation June 5, 2024 Honoring Other’s Wishes December 22, 2023 Load more HOT NEWS EMA Recommends Extending Indications for Decitabine / Cedazuridine FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... Time to take on 9 new Cancer Grand Challenges Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause...
